FRAZIER LIFE SCIENCES MANAGEMENT L P
Q4 2022 Form 13-F
PALO ALTO, CALIFORNIA
CIK 0001892134
· CRD 317522
· SEC-registered investment adviser
$1.6B Reported Value Total
FRAZIER LIFE SCIENCES MANAGEMENT, LP reports 8 total accounts under management (AUM). There are 8 discretionary accounts valued at $3,576,923,882, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
9 funds
· $7.3B gross asset value
Venture Capital Fund: $3.3B · Hedge Fund: $3.2B · Private Equity Fund: $783.7M
Source: Form ADV filed 2026-03-31
Reported value
$1.6B
Quarter over quarter
+12.0%
Holdings
44
Top-10 concentration
66.4%
Key People
Form ADV owners & control persons
Patrick James Heron
MEMBER
James Newman Topper
MEMBER
James Brush
GENERAL PARTNER & PORTFOLIO MANAGER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q4 2022 13F record
Q4 2022 13F filing summary
| Period of report | December 31, 2022 |
|---|---|
| Filed | February 03, 2023 |
| Form | 13F-HR |
| Reported value | $1.6B |
| Positions | 44 |
| Change in reported value | +23.9% |
| New positions | 7 |
| Exited positions | 6 |
| Position turnover | 26.0% |
| Top-10 concentration | 66.4% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 14, 2026
|
41 | $4.6B |
|
Q1 2026 13F
Filed May 15, 2026
|
38 | $3.9B |
|
Q4 2025 13F
Filed Feb 13, 2026
|
40 | $3.7B |
|
Q3 2025 13F
Filed Nov 14, 2025
|
47 | $3.3B |
|
Q2 2025 13F
Filed Aug 14, 2025
|
49 | $2.5B |
|
Q1 2025 13F
Filed May 15, 2025
|
47 | $2.2B |
|
Q4 2024 13F
Filed Feb 18, 2025
|
50 | $2.4B |
|
Q3 2024 13F
Filed Nov 15, 2024
|
53 | $2.5B |
|
Q2 2024 13F
Filed Aug 15, 2024
|
49 | $2.1B |
|
Q1 2024 13F
Filed May 15, 2024
|
50 | $2.4B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
49 | $1.9B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
51 | $1.5B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
48 | $1.7B |
|
Q1 2023 13F
Filed May 15, 2023
|
49 | $1.4B |
|
Q4 2022 13F
Filed Feb 3, 2023
|
44 | $1.6B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
43 | $1.3B |
|
Q2 2022 13F
Filed Aug 10, 2022
|
41 | $1.1B |
|
Q1 2022 13F
Filed May 16, 2022
|
42 | $1.2B |
Top 20 holdings · Q4 2022
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | HLVX HILLEVAX INC | $163.3M | 10.15% |
| 2 | IMGO IMAGO BIOSCIENCES INC | $143.3M | 8.91% |
| 3 | ARQT ARCUTIS BIOTHERAPEUTICS INC | $128.5M | 7.99% |
| 4 | KDNY CHINOOK THERAPEUTICS INC | $113.9M | 7.08% |
| 5 | NAMS NEWAMSTERDAM PHARMA COMPANY | $101.8M | 6.33% |
| 6 | SNDX SYNDAX PHARMACEUTICALS INC | $94.4M | 5.87% |
| 7 | PHAT PHATHOM PHARMACEUTICALS INC | $94.3M | 5.86% |
| 8 | KRYS KRYSTAL BIOTECH INC | $79.2M | 4.92% |
| 9 | MIRM MIRUM PHARMACEUTICALS INC | $75.3M | 4.68% |
| 10 | VRNA VERONA PHARMA PLC | $73.6M | 4.57% |
| 11 | PCVX VAXCYTE INC | $67.0M | 4.17% |
| 12 | RYTM RHYTHM PHARMACEUTICALS INC | $55.2M | 3.43% |
| 13 | ALLK ALLAKOS INC | $40.3M | 2.51% |
| 14 | ANAB ANAPTYSBIO INC | $27.9M | 1.73% |
| 15 | TARS TARSUS PHARMACEUTICALS INC | $26.2M | 1.63% |
| 16 | CRNX CRINETICS PHARMACEUTICALS IN | $25.9M | 1.61% |
| 17 | REPL REPLIMUNE GROUP INC | $25.3M | 1.58% |
| 18 | COGT COGENT BIOSCIENCES INC | $24.4M | 1.52% |
| 19 | ALPN ALPINE IMMUNE SCIENCES INC | $21.9M | 1.36% |
| 20 | KALV KALVISTA PHARMACEUTICALS INC | $21.9M | 1.36% |
Values as reported on the Q4 2022 Form 13F. Every position is in the holdings table below.